CoLucid

CoLucid was founded in 2005 to advance innovative drug candidates with the potential to provide safe and effective treatments for central nervous system disorders. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders.

CoLucid asked iMarc to create a new website that would elevate its online presence to communicate with investors and potential parnters in the biotechnology field. Project objectives included:

• Encourage partnerships, investment, and potential acquisition with relevant and accessible content;
• Create new look and feel, reflecting current life sciences design trends;
• Improve administrative efficiency with iMarc's powerful and easy-to-use "SiteManager" content management tools.